von Tobias Borgers | Nov 28, 2021 | Boehringer
For 2021, Boehringer Ingelheim expects to achieve a slight year-on-year increase in net sales on a comparable basis Germany-based pharmaceutical firm Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines...
von Tobias Borgers | Nov 23, 2021 | Bayer
Amid a flurry of moves by major pharmaceutical companies to separate themselves from their consumer health businesses, investors in companies that are resisting change are asking the question: Why not us? On Thursday, Bayer CEO Werner Baumann addressed the elephant in...
von Tobias Borgers | Nov 16, 2021 | Markt
Growing prevalence of diseases is driving the growth of Saudi Arabia generic drugs market during the forecast period.According to TechSci report on, “Saudi Arabia Generic Drugs Market By Type (Small Molecule Generics v/s Biosimilars), By Mode of Drug Delivery (Oral,...
von Tobias Borgers | Nov 9, 2021 | Markt
PharmStars, the only pharma-focused, member-based accelerator for digital health startups, is pleased to announce that Sumitovant Biopharma has become its newest pharma member, joining existing members including Boehringer Ingelheim, Eli Lilly and Company, and Novo...
von Tobias Borgers | Nov 9, 2021 | Markt
Cyber-physical attacks against pharma supply chains are growing because attackers have figured out how to penetrate endpoint gaps between operations technology (OT) and IT systems. What makes these attacks so lethal is how they compromise the physical security of...
